Abeona Therapeutics Inc. (ABEO) Earns Buy Rating from Cantor Fitzgerald
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a research note issued to investors on Friday. They currently have a $21.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 13.21% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the stock. Maxim Group set a $17.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Thursday, August 24th. BidaskClub downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $22.00 target price on shares of Abeona Therapeutics in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.50.
Shares of Abeona Therapeutics (NASDAQ ABEO) traded down 4.54% during mid-day trading on Friday, reaching $17.66. The company’s stock had a trading volume of 802,944 shares. Abeona Therapeutics has a 52 week low of $4.05 and a 52 week high of $18.90. The company’s 50-day moving average is $13.68 and its 200-day moving average is $8.15. The stock’s market capitalization is $711.47 million.
Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. Equities analysts predict that Abeona Therapeutics will post ($0.68) EPS for the current year.
Large investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics in the second quarter valued at about $122,000. Family Management Corp acquired a new stake in Abeona Therapeutics in the first quarter valued at about $120,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics in the second quarter valued at about $190,000. Schwab Charles Investment Management Inc. acquired a new stake in Abeona Therapeutics in the second quarter valued at about $264,000. Finally, Bank of New York Mellon Corp lifted its position in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 23,358 shares during the period. Hedge funds and other institutional investors own 38.38% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.